Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekSTAT News ↗
A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary h…
The WeekAJMC ↗
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple Negative Breast Cancer…
The WeekBioPharma Dive ↗
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene the…
The WeekPharmaVoice ↗
Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action.…
The WeekFiercePharma ↗
AstraZeneca has partnered with YMCA of the USA to increase awareness of cancer screening and early detection.…
The WeekFierceBiotech ↗
Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year aft…
The WeekBriefing
The FDA approved Trodelvy for first-line triple-negative breast cancer regardless of PD-L1 status, days after …
The WeekSTAT News ↗
It's an unusual time to be in the vaccine business. But in the view of those gathered at the BIO conference th…
The WeekAJMC ↗
Stigma and Delayed Diagnosis Are Driving Up Obstructive Sleep Apnea Costs…
The WeekBioPharma Dive ↗
The startup claims to have a "differentiated" antibody that can provide long-lasting protection against a vari…
The WeekPharmaVoice ↗
A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather th…
The WeekPharmaVoice ↗
Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over …
The WeekFiercePharma ↗
Julianne Hough is the new face of Revance's Botox rival Daxxify. The company has enlisted the dancer, actress …
The WeekFierceBiotech ↗
An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch …
The WeekBriefing
Serapha Bio forms via Boundless Bio reverse merger, backed by $230M to advance SERP-01, a China-derived base-e…
The WeekSTAT News ↗
"With the right structure, Americans will roll up their sleeves, do the science, and trust the result," Manous…
The WeekAJMC ↗
Balancing Cost, Utilization, and Risk in CLL Treatment: Adam Kittai, MD…
The WeekBioPharma Dive ↗
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some…
The WeekPharmaVoice ↗
In interviews as well as a panel at BIO's annual meeting, investors and life sciences bankers predicted an acc…
The WeekPharmaVoice ↗
Aquestive's fast response to an FDA rejection reveals why some drugmakers are betting on domestic operations d…
The WeekFiercePharma ↗
Amid efforts in Germany to retool the country's drug spending, the U.S. is launching an investigation into wha…
The WeekFierceBiotech ↗
Exelixis' next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of anal…
The WeekBriefing
China grants CARsgen approval for a Claudin18.2-targeted therapy, marking the first CAR-T authorized for solid…
The WeekDrug Channels ↗
By Adam J. Fein, Ph.D. and Greis Kapexhiu It's time for Drug Channels' annual look at pharmacist salaries and …
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.